Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Transposon announces Phase 2 results for TPN-101 in treating C9orf72-related ALS and frontotemporal dementia

and aging-related diseases, including Alzheimer's disease, announced final results from its Phase 2 study of TPN-101 in patients with amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD) related to hexanucleotide repeat...

Prolacta Bioscience Leads in Human Milk Science, Regularly Reviewing Health Claims with FDA

Prolacta Bioscience®, the world's leading hospital provider of 100% human milk-based nutritional products, takes its obligation to the critically ill and premature infants it serves, and to the doctors providing them with care, extremely...

MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent

targeted immunotherapies for cancer, today announces positive treatment updates from its Phase 2 clinical trial, THIO-101, evaluating THIO sequenced with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in patients with advanced...

Cytoki Pharma Announces Positive Phase 1 Data Showing Potential of CK-0045 to Improve Cardiometabolic Risk Factors

medicines that harness IL-22 biology to drive improved outcomes for metabolic disease, announced positive data from a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of CK-0045, its lead lipidated IL-22 candidate, in healthy...

Nature Study Reveals: AI and Molecular Dynamics Designed BGM0504 Exhibits Superior Potency

The molecular design strategy and experimental results of Bright Gene's dual GLP-1/GIP receptor agonist, BGM0504, have been published online in Scientific Reports, a sub-journal of Nature, on July 19, 2024. Bright Gene (Stock Code: 688166.SH) is...

SHINE Technologies Showcases FLARE™, the World's Most Powerful Continuous Fusion Neutron System

the US to meet stricter timelines, and rapidly respond to challenges or threats. FLARE delivers the highest steady-state 14 MeV neutron source in the industry for radiation-hardened microelectronics and fusion component testing. It's also the...

Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.

Inc. (Nasdaq: NBIX) announced the launch of a new sprinkle formulation of INGREZZA® (valbenazine) capsules, the #1 prescribed vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia and...

Biotheryx Announces First Patient Dosed in Phase 1 Clinical Trial of BTX-9341

on validated targets in cancer and inflammatory diseases, announced that the first patient has been dosed in its Phase 1 clinical trial evaluating BTX-9341. An investigational oral and bifunctional degrader of cyclin-dependent kinase 4 (CDK4) and...

Cytonics Begins First-In-Human Phase 1 Clinical Study for CYT-108 in Osteoarthritis Knee Patients

company developing biologic therapies for musculoskeletal ailments, announced initiation of enrollment for its Phase 1 clinical study of CYT-108. A recombinant variant of the alpha-2-macroglobulin blood serum protein, targeting proteases...

BARDA and Tiba Biotech Collaborate to Develop Next-Gen Influenza Therapeutics

to emerging viral threats. Tiba Biotech's initial focus will be on developing a prototype RNAi-based therapeutic for H1N1 influenza that targets the highly conserved viral nucleoprotein and will be delivered via Tiba's RNABLTM platform. "We are...

AusperBio's AHB-137 Receives Breakthrough Therapy Designation for Chronic Hepatitis B Treatment

for achieving functional cure in chronic hepatitis B (CHB) infection, announced that their investigational drug AHB-137 has received Breakthrough. Therapy Designation (BTD) from the Center for Drug Evaluation (CDE) of the National Medical Products...

Leqembi Secures Approval for Alzheimer's Disease Treatment in Hong Kong

Clarity AD study, Leqembi met its primary endpoint and all key secondary endpoints with statistically significant results.[1] In Hong Kong, 9.3% of people aged 70 years and older are living with dementia, and 32% of those aged 85 years and older,...

Genentech to Reintroduce Susvimo for Wet Age-related Macular Degeneration (AMD) Treatment

a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced the reintroduction of Susvimo® (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people in the United States (U.S.) with wet, or...

PharmAbcine's Phase 1 Trial of PMC-403 for Neovascular Age-Related Macular Degeneration Advances to Single-Dose (4mg) and Multiple-Dose (3mg)

macular degeneration (nAMD), to the fourth single-dose group of 4mg and first multiple-dose group of 3mg in Phase 1 clinical trial. PMC-403 is a novel TIE2-activating antibody with the mechanism of stabilizing pathological and leaky blood vessels....

Kedrion Selected by Biotest to Distribute FDA-Approved Immunoglobulin Yimmugo® in the U.S

agreement, Biotest is expected to begin supplying Yimmugo® to Kedrion in Q4 2024, with a market launch planned for Q1 2025. The U.S. IG market is expected to grow by roughly 9% per year in the next eight years, representing an increasing patient...

FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma

(NHL) that arises from B-lymphocytes and is the second most common form of NHL accounting for 20-30% of all cases.2 About 15,000 people develop FL each year in the U.S.3 and it is considered incurable with current standard of care therapies.4...

CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis

results in multiple completed efficacy clinical trials. CalciMedica has completed a Phase 2b trial (called CARPO – NCT04681066) in AP with SIRS and a Phase 2b trial (called CARDEA – NCT04345614) in COVID pneumonia patients, continues to support the...

Hyundai Bioscience Develops Multi-Treatment for Mosquito-Borne Viral Infections, Including Dengue Feve

replication of these viruses. Currently, there is no treatment for dengue fever. The dengue virus has four serotypes (DENV-1, DENV-2, DENV-3, DENV-4), each with different IC50 values. The IC50 values for Zika, Chikungunya, and Yellow Fever viruses,...

Smart Cups Sets New Goals For Fundraising Round Amid Upcoming Partnerships And Continued Growth

honored by TIME Magazine, receiving high recognition for their proprietary technology with a Special Mention in TIME's 2021 Best Inventions. Led by CEO Chris Kanik, who is the season one winner of Gordon Ramsay's Food Stars on FOX, the Southern...

Rigaku Analytical Devices Partners with Leading Pharmaceutical Supplier

Rigaku Analytical Devices, a pioneer in developing handheld 1064 nm Raman analyzers, is pleased to announce distribution relationship Avantor, a leading provider of mission-critical products and services to the life sciences and advanced...